ONCOVISTA INNOVATIVE THERAPIES INC

As of September 30, 2015, ONCOVISTA INNOVATIVE THERAPIES INC carries a market capitalization of 9.89M, placing it among publicly traded companies globally. Its enterprise value stands at 10.31M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of September 30, 2015, ONCOVISTA INNOVATIVE THERAPIES INC has 23.56M shares outstanding.

These figures are as of September 30, 2015.

As of September 30, 2015, ONCOVISTA INNOVATIVE THERAPIES INC maintains a current ratio of 0.01, meaning it holds 0.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -7.27, indicating conservative leverage, while an interest coverage ratio of -162.36 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended September 30, 2015. Return on assets (ROA) is negative at -3,623.77, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 2.00, a quick read on workforce productivity versus industry peers.

As of the close on October 8, 2026, ONCOVISTA INNOVATIVE THERAPIES INC's stock has gained approximately 0.00% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.03.

Over the twelve months ended September 30, 2015, ONCOVISTA INNOVATIVE THERAPIES INC generated - - in revenue and converted that into -3.27M in net income, yielding earnings per share of -0.15. EBITDA reached -3.40M, while operating income came in at -3.40M.

As of September 30, 2015, ONCOVISTA INNOVATIVE THERAPIES INC holds 61,270.00 in cash and equivalents against 479,298.00 in total debt, resulting in a net debt position of 418,028.00. Total book value stands at -6.59M, with working capital of -5.89M providing operational flexibility.

ONCOVISTA INNOVATIVE THERAPIES INC produced -264,361.00 in operating cash flow over the twelve months ended September 30, 2015.

These figures cover the twelve months ended September 30, 2015. Free cash flow yield is negative at -2.83: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -2.53, meaning ONCOVISTA INNOVATIVE THERAPIES INC raised more capital through share issuance and new debt than it returned via dividends and buybacks.

ONCOVISTA INNOVATIVE THERAPIES INC's most recent stock split took place on October 29, 2007 with a 424:625 split ratio.

As of September 30, 2015, ONCOVISTA INNOVATIVE THERAPIES INC has an Altman Z-Score of -928.52, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.